CB1 receptor signaling at the cingulate-striatal circuit is anxiogenic
Thomas J. Kelly, Xiaojie Liu, Yao Huang, Ying Hu, Vladislav Friedman, Cecilia J. Hillard, Qing-Song Liu
Nature Communications April 8, 2026 DOI: 10.1038/s41467-026-71574-x (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Experimental study with optogenetics and fiber photometry in mice Peer reviewed |
|---|---|
| Population | Mice |
| Intervention | pathway-specific deletion of CB1 receptors |
| Keywords | Anxiogenic Cannabinoid receptor Optogenetics Endocannabinoid system Excitatory postsynaptic potential Neurotransmission Biological neural network Anterior cingulate cortex Striatum |
| Key findings | CB1 receptor-mediated suppression of the ACC → DMS pathway drives anxiety-like behavior and THC aversion in mice. |
Abstract
Cannabinoids, such as Δ9-tetrahydrocannabinol (THC), produce anxiety at high doses, yet the underlying neural mechanisms remain poorly understood. The anterior cingulate cortex (ACC) sends dense monosynaptic projections to the dorsomedial striatum (DMS). Optogenetic excitation of the ACC → DMS pathway promotes anxiolytic-like behavior, suggesting that its suppression could induce anxiogenic states. We hypothesized that CB1 receptor-mediated suppression of this circuit contributes to cannabinoid-induced anxiogenic effects. We found that endocannabinoid (eCB) system components are expressed in ACC → DMS neurons and that cannabinoids depress excitatory transmission in this circuit in mice. Additionally, in vivo fiber photometry revealed that anxiogenic and aversive stimuli trigger eCB release from the DMS, which activates CB1 receptors on ACC axon terminals. Notably, pathway-specific deletion of CB1 receptors in the ACC → DMS circuit reduced both innate anxiety-like behaviors and conditioned place aversion to THC in mice. Collectively, these findings identify a circuit-level mechanism whereby cannabinoid signaling promotes anxiety and aversion. ∆9-tetrahydrocannabinol induces anxiety at high doses, but the neural mechanisms remain unclear. Here, authors show that CB1 receptor–mediated inhibition of the ACC → DMS pathway drives anxiety-like behavior and THC aversion in mice.